In recent years, pharmacists are increasingly concerned about the emergence of so-called superbugs – microorganisms resistant to most known antibiotics. And to destroy them need to create “superactivity”.
Recently published findings demonstrate that optimized arylomycin analogues such as G0775 could translate into new therapies to address the growing threat of multidrug-resistant Gram-negative infections.
The study is headed by Dr. Hans Christian Graham of Genentech, a biotech corporation that was founded in 1976 and became a Roche subsidiary in 2009. The development is conducted in the framework of the project G0775.
According to one classification bacteria are divided into 2 types: gram-positive and gram-negative. The first in the structure have an outer membrane that prevents the penetration of foreign agents inside. That’s what gives them stability, but on the surface of the membrane is peptidoglycan, which is a target for antibiotics. Bacteria from the second category also have peptidoglycan, but it is “hidden” between the two membranes, which is extremely difficult to combat these pathogens.
The research findings reported about chemical optimization of the arylomycins – a class of natural products with weak activity and limited spectrum – to obtain G0775, a molecule with potent, broad-spectrum activity against Gram-negative bacteria. The new molecule is much more efficient than the existing G0775. It has much better permeability. G0775 was already tested for resistance to 13 antibiotics and showed high efficiency.
But, despite the positive results, to create new medicines still far. According to researchers it’s too early to say that the discovery of a new type of compounds that can block the signal processes will revolutionize medicine in the near future. Scientists will continue to modify G0775 to destroy other strains of bacteria that are already not affected by common antibiotics.